On the stock market since 2010, it operates in the world of health and science. It has 37,000 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
No real growth (4% a year). Red columns mark years that ended in a loss.
The gap is $13.5B. In times of high interest rates, a gap like that can squeeze a company.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
Nothing in the current numbers stands out as a clear risk. Still, no stock is ever risk-free.
On our five-subject report card, TEVJF sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: TEVJF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.